Testing a new lung cancer drug for uncommon genetic mutations

This trial is testing a new medication called befotertinib for people with advanced lung cancer that has specific uncommon genetic changes. The medication is designed to target and attack cancer cells that have one of these genetic mutations. Researchers want to find out whether the medication works well and whether it's safe for patients like you.

Most lung cancer medications work best against the most common genetic mutations, but some people have rarer genetic changes that don't respond as well to standard treatments. This trial exists to see if this new medication can help patients whose cancers have these less common mutations.